Giri Babu Veerakanellore

Giri Babu Veerakanellore

Auto-generated profile, based on publicly available information

Giri Babu Veerakanellore

Center for Clinical Pharmacology, Washington University School of Medicine and University of Health Sciences and Pharmacy, St. Louis, Missouri 63110, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SGShaimaa S. Goher
Shaimaa S. Goher
WAWessam S. Abdrabo
Wessam S. Abdrabo
GVGiri Babu Veerakanellore
Giri Babu Veerakanellore
Bahaa ElgendyBahaa Elgendy
Bahaa Elgendy
2,5-Diketopiperazine (2,5-DKP) derivatives represent a family of secondary metabolites widely produced by bacteria, fungi, plants, animals, and marine organisms. Many natural products with DKP scaffolds exhibited various pharmacological activities such as antiviral, antifungal, antibacterial, and antitumor. 2,5-DKPs are recognized as privileged structures in medicinal chemistry, and compounds that incorporate the 2,5-DKP scaffold have been extensively investigated for their anticancer properties. This review is a thorough update on the anti-cancer activity of natural and synthesized 2,5-DKPs from 1997 to 2022. We have explored various aspects of 2,5-DKPs modifications and summarized their structure-activity relationships (SARs) to gain insight into their anticancer activities. We have also highlighted the novel approaches to enhance the specificity and pharmacokinetics of 2,5-DKP-based anticancer agents.

1 November 2021 in Journal of Photochemistry and Photobiology A: Chemistry
Verified
Journal Article
Closed access
VJVaitheesh Jeyapalan
Vaitheesh Jeyapalan
RVRamkumar Varadharajan
Ramkumar Varadharajan
GVGiri Babu Veerakanellore
Giri Babu Veerakanellore
VRV. Ramamurthy
V. Ramamurthy